Scotiabank Reiterates Sector Perform Rating for Blueprint Medicines (NASDAQ:BPMC)
Scotiabank reiterated their sector perform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday morning,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. Needham & Company LLC reiterated a “hold” rating and […]
Scotiabank reiterated their sector perform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report released on Monday morning,Benzinga reports. They currently have a $135.00 price objective on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. Needham & Company LLC reiterated a “hold” rating and […]
